The bill HB 1772-FN-A introduces two major changes to healthcare law in New Hampshire. Firstly, it permits licensed healthcare providers to administer ibogaine, a substance utilized in specific treatment protocols, under an FDA-approved research protocol. This is achieved by adding a new section, RSA 329:1-i, which allows licensed physicians or qualified practitioners to administer ibogaine in accordance with federal law. Secondly, the bill adopts the Physician Associate (PA) Licensure Compact, which facilitates the practice of PAs across participating states under a single license. A new section, RSA 328-D:18-a, outlines the compact's provisions, including mutual recognition of licenses, jurisdictional authority, and the establishment of a data system for licensee information, while also implementing requirements such as criminal background checks and the ability to impose adverse actions against licensees.

Additionally, the bill details the governance and operational procedures for the PA Licensure Compact Commission, which will oversee the compact's implementation. It includes provisions for the commission's authority, such as the ability to bring legal actions, manage finances, and establish rules with the force of law across participating states. The bill also emphasizes transparency in the commission's operations, requiring public access to meetings and the maintenance of accurate financial records. Key insertions in the bill enhance the sharing of investigative information among states, while deletions streamline the governance process. The fiscal impact of the bill is projected to be indeterminable, with an estimated one-time cost of $10,000 for implementation and a potential revenue loss of approximately $93,000 due to PAs opting for compact privileges instead of maintaining a New Hampshire license. The bill is set to take effect 60 days after passage.

Statutes affected:
Introduced: 6:12
HB1772 text: 6:12